Dobutamine in the Treatment of Haemodynamic Insufficiency in the Immediate Postnatal Period

NCT03311178 | Terminated Phase 1 DMC

• 1 other identifier: Neocirculation 001
• Study Type: interventional
• Target: 15
• Locations: 1 country
• Sites: 1

Brief Summary

Haemodynamic insufficiency after birth is seen commonly in babies born prematurely and is associated with adverse outcomes. In current clinical practice, a combination of blood pressure and clinical signs is used to guide therapy. However, blood pressure is a poor surrogate of systemic and organ (brain) blood flow distribution during transitional circulation. This state is characterised by increased peripheral vascular resistance and increased afterload causing myocardial depression and impaired blood flow distribution in spite of 'normal' blood pressure. Echocardiography-Doppler (Echo-D) measurement of superior vena cava (SVC) flow has been proposed as a more clinically relevant marker of circulatory impairment shortly after birth than systemic hypotension. When there is low SVC flow, several small-scale clinical trials have suggested dobutamine as the optimal therapeutic option. However the associations between SVC flow and short- and long- term outcomes are not strong enough to allow SVC flow alone to be the basis for the inclusion of patients into a confirmatory trial to demonstrate the efficacy and safety of dobutamine. NeoCirc-001 - The primary objective is to answer some important questions required for the design of a subsequent placebo-controlled trial (NeoCirc-003), which will evaluate the effectiveness of a new neonatal formulation of dobutamine to treat haemodynamic insufficiency in the first 72 hours after birth in babies born at less than 33 weeks' gestation. Observational data will be collected from this population with a view to determining the degree to which diagnostic measures influence treatment decisions. The primary outcome is death or worst cranial ultrasound (CUS) appearance at or before 36 weeks' gestation. NeoCirc-001A - The primary objective is to estimate the elimination half-life, and consequently the time to steady-state of dobutamine in extremely premature neonates. NeoCirc-001B - The primary objective is to construct a population pharmacokinetic pharmacodynamic model that will be validated using samples collected during the confirmatory trial (NeoCirc-003).

Conditions

Shock

Keywords

Shock; Preterm infant; Dobutamine

Outcome Measures

Primary Outcomes (2)

• Mortality, or intraventricular haemorrhage (IVH) grades 3 or 4, or cystic and non-cystic periventricular leukomalacia (PVL), or porencephalic cysts, ventriculomegaly, or cerebellar haemorrhage.

  A composite endpoint is defined as follows: treatment failure is when one of the following is true at or before gestational age 36 (+/-2 weeks), when all surviving patients will have a cranial ultrasound (CUS)- 1. Neonate dies, or 2. Intraventricular haemorrhage (IVH) grades 3 or 4, or 3. cystic and non-cystic periventricular leukomalacia (PVL), or 4. porencephalic cysts, ventriculomegaly, or cerebellar haemorrhage.

  at 36 (+/-2 weeks) postmenstrual age

• Half-life of the neonatal formulation of dobutamine.

  NeoCirc-001A: Half-life of the neonatal formulation of dobutamine. The first sample will be drawn after the end of the infusion, at the time when dobutamine ceases reaching the systemic circulation of the neonate, defined as time end (te). To calculate the end of infusion (te) the dead space used in each unit will be taken into account (see below). The second sample will be taken at different study time points after the end of infusion: * 5 min after te * 15 min after te * 45 min after te * 2 hours after te * 6 hours after te Two infants will be allocated to each time point. Sampling times will be assigned randomly to the patients.

  The first sample will be drawn after the end of the infusion, at the time when dobutamine ceases. The second sample will be taken at different study time points after the end of infusion (from 5 min to 6 hours).

Secondary Outcomes (27)

• Arterial blood pressure

  First 72 hours of life (data collection every 9 ±3 hrs)

• Capillary refill time

  First 72 hours of life (data collection every 9 ±3 hrs)

• Urine output

  First 72 hours of life (data collection every 9 ±3 hrs)

• Blood lactate concentration

  First 72 hours of life (data collection every 9 ±3 hrs)

• Base excess

  First 72 hours of life (data collection every 9 ±3 hrs)

Other Outcomes (1)

• Number of participants with adverse events

  Daily during the first four days of life, at 36±2 weeks' gestation or discharge and at 38±2 weeks' gestation or discharge

Study Arms (1)

Dobutamine

EXPERIMENTAL

Infants who meet the definition of poor perfusion state will be treated at the discretion of the responsible physician following the standard local policies. The interventions will be dobutamine from a new neonatal formulation developed for NeoCirc and/or other treatments (including any other cardiovascular drug or volume replacement with normal saline).

Drug: Dobutamine

Interventions

Dobutamine DRUG

Infants who meet the definition of poor perfusion state will be treated at the discretion of the responsible physician following the standard local policies. The interventions will be dobutamine from a new neonatal formulation developed for NeoCirc and/or other treatments (including any other cardiovascular drug or volume replacement with normal saline).

Dobutamine

Eligibility Criteria

• Age: Up to 72 Hours
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17)

You may qualify if:

• Target population for informed consent:
• neonates 24 to 32+6 weeks´ gestation,
• postnatal age \<72 hours;
• Infants eligible for circulatory failure pathway:
• parental informed consent obtained;
• The infants will be assessed, as per routine clinical practice, for clinical signs indicating infants at risk of poor perfusion, and will be recruited if they develop haemodynamic insufficiency defined as: either two or more of: (i) Mean blood pressure (MBP) \< gestational age (GA)-1 mmHg (invasive/non-invasive, two readings 15 min apart); (ii) SVC flow \< 51 ml/kg/min; (iii) capillary refill time (CRT) \> 4 sec; (iv) Lactate \> 4 mmol/l (v) Base excess \<-9 mmol/l or: MBP \< GA -5 mmHg (invasive/non-invasive, two readings 15 min apart)

You may not qualify if:

• non-viability;
• congenital hydrops or malformations likely to affect cardiovascular adaptation;
• surgery planned within 72 hours of birth;
• chromosomal anomalies;
• informed consent form (ICF) not signed.

Sponsors & Collaborators

• Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz: lead
• Hospital Universitario La Paz: collaborator
• Brighton and Sussex University Hospitals NHS Trust: collaborator
• University of Luebeck: collaborator
• Servicio Vasco de Salud Osakidetza, Spain: collaborator
• University of Liverpool: collaborator
• Vest Children´s Hospital, Germany: collaborator
• Datteln University Witten-Herdecke: collaborator
• Iuliu Hatieganu University of Medicine and Pharmacy: collaborator
• Semmelweis University: collaborator
• University of Pecs: collaborator
• Gazi University: collaborator
• Tufts Medical Center: collaborator
• Hannover Medical School: collaborator
• Onorach Clinical Dundee, Scotland: collaborator
• Proveca Limited Daresbury, England: collaborator
• Institut National de la Santé Et de la Recherche Médicale, France: collaborator

Study Sites (1)

La Paz University Hospital, Department of Neonatology

Madrid, 28046, Spain

Location

Related Publications (4)

• Kluckow M, Evans N. Low superior vena cava flow and intraventricular haemorrhage in preterm infants. Arch Dis Child Fetal Neonatal Ed. 2000 May;82(3):F188-94. doi: 10.1136/fn.82.3.f188.

  PMID: 10794784 BACKGROUND

• Kluckow M, Evans N. Superior vena cava flow in newborn infants: a novel marker of systemic blood flow. Arch Dis Child Fetal Neonatal Ed. 2000 May;82(3):F182-7. doi: 10.1136/fn.82.3.f182.

  PMID: 10794783 BACKGROUND

• Osborn DA, Paradisis M, Evans N. The effect of inotropes on morbidity and mortality in preterm infants with low systemic or organ blood flow. Cochrane Database Syst Rev. 2007 Jan 24;2007(1):CD005090. doi: 10.1002/14651858.CD005090.pub2.

  PMID: 17253539 BACKGROUND

• Dempsey EM, Barrington KJ. Treating hypotension in the preterm infant: when and with what: a critical and systematic review. J Perinatol. 2007 Aug;27(8):469-78. doi: 10.1038/sj.jp.7211774.

  PMID: 17653217 BACKGROUND

MeSH Terms

Conditions

Shock; Premature Birth

Interventions

Dobutamine

Condition Hierarchy (Ancestors)

Pathologic Processes; Pathological Conditions, Signs and Symptoms; Obstetric Labor, Premature; Obstetric Labor Complications; Pregnancy Complications; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases

Intervention Hierarchy (Ancestors)

Catecholamines; Amines; Organic Chemicals; Phenethylamines; Ethylamines; Catechols; Phenols; Benzene Derivatives; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons

Study Officials

• Adelina Pellicer, MD PhD

  SERMAS La Paz University Hospital

  STUDY CHAIR

• Heike Rabe, MD PhD

  Brighton and Sussex University Hospitals (BSUH)

  STUDY DIRECTOR

• Fernando Cabañas, MD PhD

  Servicio Madrileño de Salud (SERMAS)

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Chief Investigator

Study Record Dates

• First Submitted: May 27, 2014
• First Posted: October 17, 2017
• Study Start: May 30, 2014
• Primary Completion: October 13, 2015
• Study Completion: October 10, 2017
• Last Updated: October 17, 2017

Record last verified: 2017-10

Locations

ES (1)